General Principles - The management control of the holding subsidiaries aims to establish an effective control mechanism to manage the company's governance structure, assets, and resources, enhancing overall operational efficiency and risk resistance [2][3][4] - The company exercises shareholder rights through voting and appointing directors, supervisors, and senior management to the holding subsidiaries, while also providing guidance, supervision, and related services [2][3] Management of Holding Subsidiaries - Holding subsidiaries must establish operational plans and risk management procedures in accordance with the company's business strategy and risk management policies [3][4] - Holding subsidiaries are required to report significant business and financial matters to the company in a timely manner, following the company's major matters reporting system [3][4][5] Establishment and Governance Structure - The establishment of holding subsidiaries must comply with national laws and regulations, align with the company's development strategy, and avoid blind expansion [4][5] - Holding subsidiaries must develop their articles of association in consultation with other shareholders and establish a sound internal management system [5][6] Supervision and Management - The company has the right to audit and inspect the operations and finances of holding subsidiaries, providing corrective recommendations as necessary [8][9] - Holding subsidiaries must adhere to the company's unified financial management policies and accounting systems, with the company's finance department overseeing their financial management [8][9] Information Disclosure - Significant events occurring in holding subsidiaries are treated as significant events for the company, requiring timely reporting to the company's board of directors [10][11] - The heads of holding subsidiaries are responsible for reporting information that may significantly impact the company's stock and derivatives trading prices [10][11]

塞力斯医疗科技集团股份有限公司 控股股东、实际控制人行为规范 第三条 控股股东、实际控制人应当遵守诚实信用原则，依法行使股东权利、 履行股东义务，依规签署并恪守有关声明和承诺，不得隐瞒其控股股东、实际控 制人身份，逃避相关义务和责任。 第四条 控股股东、实际控制人应当维护公司独立性，不得滥用股东权利、 控制地位或者利用关联关系损害公司和其他股东的合法权益，不得利用对公司的 控制地位牟取非法利益。 公司的控股股东、实际控制人不担任公司董事但实际执行公司事务的，对公 司负有忠实义务、勤勉义务。 第二章 公司治理 塞力斯医疗科技集团股份有限公司 控股股东、实际控制人行为规范 （2025年8月） 第一章 总则 第一条 为进一步完善塞力斯医疗科技集团股份有限公司(以下简称"公 司")的法人治理结构，规范控股股东、实际控制人对公司的行为，保护公司和 股东的合法权益。根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司治理准则》《上海证券交易所股票上市规则》《上海证券交易所上市公司 自律监管指引第 1 号——规范运作》等法律、法规、规章、规范性文件及《塞力 斯医疗科技集团股份有限公司章程》（以下简称"《公司章程 ...

塞力斯医疗科技集团股份有限公司 董事会战略委员会实施细则 塞力斯医疗科技集团股份有限公司 董事会战略委员会实施细则 （2025年8月） 第一章 总则 第一条 为适应塞力斯医疗科技集团股份有限公司（以下简称"公司"）战 略发展需要，增强公司核心竞争力，确定公司发展规划，健全投资决策程序，加 强决策科学性，提高重大投资决策的效益和决策的质量，完善公司治理结构，根 据相关法律法规及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公 司章程》"）的规定，特制定本细则。 第二条 董事会战略委员会是董事会按照股东会决议设立的专门工作机构， 主要负责对公司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会成员由五名董事组成，其中应至少包括一名独立董事。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第五条 战略委员会设召集人（即主任委员）一名，由公司董事长担任。 第六条 战略委员会任期与董事会任期一致，委员任期届满，可以连选连任。 期间如有委员不再担任公司董事职务，自动失去委员资格，并由委员会根据上述 第三至第五条规定补足委员人 ...

塞力斯医疗科技集团股份有限公司 独立董事专门会议工作制度 塞力斯医疗科技集团股份有限公司 《中华人民共和国证券法》 《上市公司独立董事管 理办法》 《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》等法律、行政法规、部门规章、规范性文件以及《塞力 斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定，特制 定本制度。 第二条 公司应当定期或者不定期召开全部由独立董事参加的会议（以下简 称"专门会议"）。专门会议应当由过半数独立董事共同推举一名独立董事召集和 主持；召集人不履职或者不能履职时，两名及以上独立董事可以自行召集并推举 一名代表主持。 公司应当为独立董事专门会议的召开提供便利和支持。 独立董事专门会议工作制度 （2025 年 8 月） 第一条 为进一步完善塞力斯医疗科技集团股份有限公司（以下简称"公司"） 治理结构，充分发挥独立董事作用，促进公司的规范运作，维护公司整体利益， 根据《中华人民共和国公司法》 （六）公司被收购时，董事会针对收购所作出的决策及采取的措施； 第三条 独立董事召开专门会议应于会议召开前三日通知全体独立董事。因 情况紧急， ...

General Principles - The purpose of the implementation rules is to establish a sound assessment and compensation management system for the board of directors and senior management of the company, improving corporate governance structure [2] - The Compensation and Assessment Committee is a specialized working body established by the board of directors and is accountable to the board [2] Composition of the Committee - The Compensation and Assessment Committee consists of three directors, with independent directors making up more than half [4] - The committee members are nominated by the chairman, more than half of the independent directors, or one-third of all directors, and elected by the board [4] - The committee has a convener (chairperson) who is an independent director, responsible for leading the committee's work [6] Responsibilities and Authority - The committee is responsible for formulating assessment standards for directors and senior management, reviewing compensation policies, and making recommendations to the board on various matters [6] - The committee's proposed compensation plans for directors must be approved by the board and submitted for shareholder approval before implementation [10] - The committee must conduct an annual review of the compensation decision-making process and report findings to the board [11] Decision-Making Procedures - The committee's working group is responsible for preparing materials related to compensation and assessment decisions [12] - The assessment process includes self-evaluation by directors and senior management, followed by performance evaluations conducted by the committee [13] Meeting Rules - Meetings of the committee are called as needed, with notifications sent three days in advance, unless urgent [10] - A quorum requires attendance from at least two-thirds of the committee members, and decisions must be approved by a majority [15] - Meeting records must be kept, and confidentiality obligations apply to all attendees [22][24] Supplementary Provisions - The rules take effect upon approval by the board and are subject to relevant national laws and regulations [26][27] - The board holds the authority to interpret these rules [28]

塞力斯医疗科技集团股份有限公司 董事会提名委员会实施细则 塞力斯医疗科技集团股份有限公司 第三章 职责权限 第七条 提名委员会负责拟定董事、高级管理人员的选择标准和程序，对董 事、高级管理人员及其任职资格进行遴选、审核，并就下列事项向董事会提出建 议： 董事会提名委员会实施细则 （2025 年 8 月） 第一章 总则 第一条 为规范塞力斯医疗科技集团股份有限公司（以下简称"公司"）领 导人员的产生,优化董事会和高级管理层的组成,完善公司治理结构,根据相关法 律法规及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，特制定本细则。 第二条 董事会提名委员会是董事会设立的专门工作机构,对董事会负责。 第二章 人员组成 第三条 提名委员会成员由 3 名董事组成，独立董事应当过半数。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名,并由董事会选举产生。 第五条 提名委员会设召集人（即主任委员）一名,由独立董事委员担任,负 责主持委员会工作；召集人在委员内选举,并报请董事会批准产生。 第六条 提名委员会任期与董事会任期一致,委员任期届满,可以连选连任。 期间如 ...

Meeting Overview - The supervisory board of the company held its ninth meeting on August 27, 2025, with all three supervisors present, and the meeting was conducted in accordance with legal and regulatory requirements [1][2] - All resolutions proposed during the meeting were approved unanimously, with no votes against or abstentions [1][2] Financial Reporting - The supervisory board reviewed and approved the company's 2025 semi-annual report and its summary, confirming that the report's preparation and review processes complied with relevant laws, regulations, and internal management systems [1] - The board stated that the information contained in the semi-annual report accurately reflects the company's financial status and operational results, with no false statements or significant omissions identified [1] Fund Utilization - The supervisory board also approved the special report on the storage and actual use of raised funds for the first half of 2025, affirming that the situation aligns with regulatory rules and guidelines [2] - The report's content was deemed truthful, accurate, and complete, with no misleading statements or significant omissions found [2]

Group 1 - The company reported a revenue of 14.529 million Singapore dollars for the six months ending June 30, 2025, representing a year-on-year decrease of 43.98% [1] - The loss attributable to shareholders was 10.253 million Singapore dollars, which is an increase of 69.67% compared to the previous year [1] - The loss per share was 0.2 Singapore cents [1]

Core Insights - The company, Jin Hai Medical Technology, reported a revenue of SGD 14.529 million for the six months ending June 30, 2025, representing a year-on-year decrease of 44% [1] - The gross profit was SGD 2.082 million, which is a significant decline of approximately 72% compared to the previous year [1] - The loss attributable to the company's owners was SGD 10.253 million, compared to a loss of SGD 6.043 million in the same period last year [1] - The basic loss per share was SGD 0.20 cents [1]

(三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025年9月16日 14 点30 分 召开地点：江苏省常州市金坛区直溪镇工业集中区健尔康路1号办公楼一楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025年9月16日 至2025年9月16日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东大会召开当日的交易时间 段，即9:15-9:25,9:30-11:30，13:00-15:00；通过互联网投票平台的投票时间为股东大会召开当日的9:15- 15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投票，应按照《上海证券交易 所上市公司自律监管指引第1号 一 规范运作》等有关规定执行。 (七)涉及公开征集股东投票权 不涉及 二、会议审议事项 本次股东大会审议议案及投票股东类型 ■ 1、各议案已披露的时间和披露媒体 本次提交股东大会审议的议案已经 ...